With co-founders from Stanford University and National University of Singapore, Nuevocor aims to develop gene therapies for cardiomyopathies.
Nuevocor, a Singapore-based developer of gene therapies for cardiomyopathies co-founded by Stanford University and National University of Singapore researchers, secured $24m in a series A round yesterday.
Pharmaceutical firm and Boehringer Ingelheim co-led the round through subsidiary Boehringer Ingelheim Venture Fund together with EVX Ventures. The round also included Xora Innovation and the state-owned EDBI and Seeds Capital as well as undisclosed other investors.
Nuevocor is working on an adeno-associated virus-based gene therapy for patients suffering from a…
Thierry Heles
Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
